SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-157454
Filing Date
2024-06-07
Accepted
2024-06-07 16:42:02
Documents
19
Period of Report
2024-06-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d841004d8k.htm   iXBRL 8-K 34519
2 EX-1.1 d841004dex11.htm EX-1.1 231883
3 EX-4.1 d841004dex41.htm EX-4.1 63684
4 EX-5.1 d841004dex51.htm EX-5.1 14913
5 EX-99.1 d841004dex991.htm EX-99.1 9982
9 GRAPHIC g841004g0606102811677.jpg GRAPHIC 2534
10 GRAPHIC g841004g0606103012142.jpg GRAPHIC 3621
  Complete submission text file 0001193125-24-157454.txt   584874

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA annx-20240605.xsd EX-101.SCH 2847
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE annx-20240605_lab.xml EX-101.LAB 18757
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE annx-20240605_pre.xml EX-101.PRE 11708
22 EXTRACTED XBRL INSTANCE DOCUMENT d841004d8k_htm.xml XML 3768
Mailing Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005
Business Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005 (650)-822-5500
Annexon, Inc. (Filer) CIK: 0001528115 (see all company filings)

IRS No.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39402 | Film No.: 241030256
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)